Mizuho lowered the firm’s price target on Kura Oncology (KURA) to $30 from $32 and keeps an Outperform rating on the shares. The firm updated the company’s model post the Q1 report.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KURA:
- Kura Oncology: Promising Clinical Trials and Stable Financials Justify Buy Rating
- Kura, Kyowa say ziftomenib abstract accepted for EHA Congress
- Kura Oncology’s Promising Market Position and Growth Prospects Justify Buy Rating
- Syndax price target raised to $17 from $16 at Scotiabank
- Kura Oncology’s Strategic Advancements and Promising Pipeline Drive Buy Rating
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue